News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Biocoral, Inc. (BCRA) Announces Approval Of Its French Patent

1/9/2006 11:24:28 AM

NEW YORK, January 9 /PRNewswire-FirstCall/ -- Biocoral, Inc. announced today that recently the French Patent Office (Institut National de la Propriete Industrielle "INPI") approved and granted a company patent called "Device for delivering of Biomaterial into a determined portion of bone"

The French Patent Office, after more then three years of examining of the company's application, granted the patent innovation to Bio Holdings International Ltd., the Company's wholly owned subsidiary, under the patent number 01 12082. The Patent will expire in 2021.

The INPI is a French Government Agency Patent Office, which contributes to the development of industry by securing and protecting the successful and creative development of structures for patents, etc. The INPI represents France in the qualified international organizations and to cooperate to support the exchanges.

Nasser Nassiri, the Chairman and Chief Executive Officer of Biocoral, Inc. commented, "the Company believes that the range of clinical orthopedics applications for the new patented Device is wide open especially the treatment of bone diseases associated with demineralization such as treatment of Hip Fracture. In addition the company is already owns patent for the use of at least one biocompatible and bioabsorbable calcium salt for local treatment of bone diseases associated with demineralization or mineralization defects of bone, with the aim of reinitiating the process of bone remineralization.

Nasser Nassiri, further commented that, "Our patent is now granted in France and we further anticipate that our pending patent applications in a number of other countries worldwide will also receive approval very soon."

About Biocoral, Inc.

Biocoral, Inc., a Delaware corporation, is an international biomaterials "tissue-engineering" company specializing in the research and development of proprietary health care patented high technologies and biomaterials.

Biocoral(r), the Company's primary product, is a natural coral "carbonate Calcium" derived bone graft substitute and is used by surgeons and practitioners because of its biocompatibility, resorbability, osseo conduction and safety. Certain chemical, physical and structural characteristics of coral are very similar to that of human bone tissue. Biocoral(r) is derived from three particular species of coral naturally present in abundance. Biocoral(r) is primarily (more than 98%) comprised of calcium carbonate. Porous and resorbable, Biocoral(r) is prepared in microgranules as well as in engineered shapes according to specific indication. Due to its similarity to bone tissue, Biocoral(r) is compatible, resorbed by the body as new bone growth invades the Biocoral(r) and is replaced by neoformed invasion. It is highly porous with numerous interconnected channels which allow a total migration to the center of the implant free of contamination risk. Because Biocoral(r) is resorbed, it can be combined with antimicrobials, anticancer agents or other pharmaceuticals for slow release into bone tissue, resulting in an advantage over autologous bone grafts. The principal current alternative to Biocoral(r) is the utilization of autologous (from the patient's own body) bone grafts. The use of autologous bone grafts requires the patient to undergo one or more additional surgeries to harvest the bone graft material. This is not always feasible due to the condition of the patient or other contraindications, and must be shaped in a separate procedure to fit the graft area.

Through its subsidiaries, the Company researches, develops, manufactures and commercializes bone graft substitutes and other high tech patented biomaterials in a number of countries outside the United States. Biocoral, Inc. through its subsidiaries has developed the additional twelve titles of patents for various applications and uses of its products, such as a method of treating a disease associated with demineralization or mineralization bone defects ("osteoporosis remediation"), and combination with growth factor, among others. With these patents titles applications in various countries in the European Community, Canada, the United States, Japan, Australia, and Switzerland, the Company owns more than 219 patent applications around the world, and approximately 165 of these have thus far been granted by various countries' official government patent offices, including most European Community countries, Canada, Australia, Japan and in the United States by the US Department of Commerce Patent and Trademark Office.

The information contained in this press release, including any "forward looking" statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 contained herein, should be reviewed in conjunction with the Company's Annual Report on Form 10-KSB and other publicly available information regarding the Company, copies of which are available from the Company upon request. Such publicly available information sets forth many risks and uncertainties related to the Company's business and such statements, including risks and uncertainties related thereto that are unpredictable and outside of the influence and/or control of the Company.

CONTACT: Biocoral, Inc., Nasser Nassiri, +33-1-4757-9843


CONTACT: CONTACT: Biocoral, Inc., Nasser Nassiri, +33-1-4757-9843

Read at

comments powered by Disqus